

## QIBA PET Amyloid Biomarker Committee

13 November 2015 at 9 AM CT

*Notes provided by Dr. Smith*

### In attendance:

#### Co-chairs:

Satoshi Minoshima, MD, PhD

Eric Perlman, MD

Anne Smith, PhD

#### Participants:

Martin Lodge, PhD

Dawn Matthews, MS, MBA

Nancy Obuchowski, PhD

Daniel Sullivan, MD

Jean-Luc Vanderheyden, PhD

Brian Zimmerman, PhD

### RSNA

Joe Koudelik

Julie Lisiecki

### Agenda:

- Final RSNA 2015 Poster
  - Staffing Poster (has open slot)
- Optimal topics to cover at RSNA f2f breakout session
- Amyloid claim update (Rathan)
- Discussion of new projects that will kick-off soon Profile review update
  - Analyses to Support Amyloid Imaging Profile Development
  - Amyloid Brain PET Test-Retest Analysis
  - A Procedure to Facilitate Greater Standardization of PET Resolution
- Profile Review – Current Status
- *Dr. Smith provided detailed meeting slides for this call - ([posted separately as a PDF on the QIBA wiki](#))*

### RSNA 2015: QIBA Working Meeting, Dec 2<sup>nd</sup>

- Plenary Session: 2:30 pm CT in **Room# E253AB**

### Suggested topics for f2f Sessions at QIBA Working Meeting:

- Claim discussion/presentation
- Follow-up beyond Profile, topics for next version
  - Add partial volume correction
  - Motion correction information from Dawn's project
  - Output from Martin's project
  - Output from Rathan's project
  - Physical and DRO phantom additions
  - PET/MRI
  - Centiloid project
  - Tau imaging
  - e.g., feasibility testing need like FDG?
    - if so, how and who could lead?
- Where is state of art on use of [volumetrics](#) for Alzheimer's? (ask an expert in this area to talk to us?)
  - Should QIBA be developing this in combo with Amyloid PET or is there logical extension to **tau** imaging?
  - Neuroinflammation markers
  - Ask Japanese colleagues to take on one of the above topics?
    - Have developed a good approach for quantitative SPECT
- Develop QIBA- engagement/collaboration with other Alzheimer groups to identify gaps or inconsistencies, etc.
  - Coalition against major diseases (CAMD): members from pharma, radiopharmaceutical industry, scanner vendors
    - Dawn will make contact with them, to gauge interest in attending f2f or attending a Netmeeting
    - Develop profiles as well
    - Part of Critical Path Institute, which had money from FDA, State of Arizona. Big area of focus is AD.
      - Moving forward with FDA, but overall not very successful, yet
      - More success in Europe with the EMA
- Update and feedback on funded projects (as time allows)
  - Martin's project

- Dawn's project
- Rathan's project
- Physical phantom and DRO (John and Paul): will have time on future Netmeeting
- Have combined time with the QIBA SPECT DaTscan group
- Profile feedback – as time allows

**Profile Review – Current Status:**

- October 29th: 1 hour Netmeeting review
- Eric will be sending follow-up email in < 2 weeks
  - request for identified actions
  - plan to then incorporate revisions in track change with updated spreadsheet and itemization of critical issues
  - any high level items for group discussion may become a topic for f2f at RSNA

**Upcoming Nuclear Medicine Calls:**

- Nov 24: SPECT Task Force #4: Clinical / Literature Review - *Dr. Seibyl* – Tuesday, 2 pm CT
- 

**SPECT Task Forces: (Tuesdays at 2 pm CT)**

- Dec 1: **No call (RSNA 2015)**
  - Dec 8: Image Acquisition and Image Processing for DaTscan – *Dr. Dewaraja*
  - Dec 15: Quantitative and Image Analysis – *Drs. Miyaoka and Seibyl*
  - Dec 22: Phantoms/ DRO Group – *Drs. Dickson and Zimmerman*
  - Dec 29: **No call (RSNA Winter Break)**
- 

**NM BC calls: (Fridays at 9 am CT)**

- Dec 11: Amyloid BC
- Dec 18: SPECT BC